Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1916)	8/23/1999 12:07:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 2028

DJ Bio-Tech Genl Gets Patent Allowance For Oxandrolone Use ISELIN, N.J. (Dow Jones)--Bio-Technology General Corp. (BTGC) received a notice of allowance for a U.S. patent for the use of oxandrolone in the treatment of HIV Wasting Syndrome. In a press release Monday, the biopharmaceutical company said the allowance follows the recent issuance of another patent, for the use of oxandrolone in patients suffering from chronic obstructive pulmonary disease. Oxandrolone is used in the treatment of involuntary weight loss associated with chronic infection, severe trauma, burns and unknown pathophysiology. Bio-Technology has been marketing oxandrolone as Oxandrin in the U.S. since 1995. The company's Nasdaq-listed shares were recently trading at 10 1/2, up 7/16 or 4.3%, on composite volume of 753,800 shares. Average daily volume is 580,320 shares.